Skip to content
SHLabz
العربيةع

Shop in

Home / Compound library / Ipamorelin

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and described in 1998 as the first selective GH secretagogue. It was studied in animal models and reached phase II clinical trials for postoperative ileus, which were stopped for lack of efficacy.

Class
growth hormone secretagogue (ghrelin receptor agonist)
Type
peptide, 5 residues
Also known as
NNC 26-0161
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH2
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
PubChem CID
20754357
First described
1998: Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 139(5):552–561.

Regulatory status

Not an approved medicine. FDA placed ipamorelin acetate in category 2 (potential significant safety risks) for 503B outsourcing-facility compounding in September 2023.

SHLabz batch results

ProductBatchPurityAmount measuredTestedReport
Ipamorelin 10 mgIP10/2025-101099.616%10.25 mg03 Nov 2025Janoshik 85662

Where SHLabz supplies it

CJC-1295 (No DAC) + Ipamorelin · CJC-1295 (No DAC) + Ipamorelin Pen · CJC-1295 + Ipamorelin Nasal Spray. For laboratory research use only.

Further reading

Sources

How to cite this sheet

SHLabz (2025). Ipamorelin: compound reference sheet. SHLabz Compound Library. https://shlabz.ae/compounds/ipamorelin/

This sheet describes a molecule and the published research on it. It is not advice about use, and SHLabz products are not for human or veterinary use.

SHLabz
Shop Research Peptides